These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 31218726)

  • 21. Comparison of ultra-fast 2D and 3D ligand and target descriptors for side effect prediction and network analysis in polypharmacology.
    Cortés-Cabrera A; Morris GM; Finn PW; Morreale A; Gago F
    Br J Pharmacol; 2013 Oct; 170(3):557-67. PubMed ID: 23826885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic-based therapy: From single- to multi-target approaches.
    Benedetti R; Conte M; Iside C; Altucci L
    Int J Biochem Cell Biol; 2015 Dec; 69():121-31. PubMed ID: 26494003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular hybridization: a powerful tool for multitarget drug discovery.
    de Sena Murteira Pinheiro P; Franco LS; Montagnoli TL; Fraga CAM
    Expert Opin Drug Discov; 2024 Apr; 19(4):451-470. PubMed ID: 38456452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Advances in Dual BRD4-Kinase Inhibitors Based on Polypharmacology.
    Chen L; Liu ZP; Li X
    ChemMedChem; 2022 Mar; 17(6):e202100731. PubMed ID: 35146935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in multitarget-directed ligands via in silico drug discovery.
    Maddeboina K; Yada B; Kumari S; McHale C; Pal D; Durden DL
    Drug Discov Today; 2024 Mar; 29(3):103904. PubMed ID: 38280625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polypharmacology: promises and new drugs in 2022.
    Ryszkiewicz P; Malinowska B; Schlicker E
    Pharmacol Rep; 2023 Aug; 75(4):755-770. PubMed ID: 37278927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling Polypharmacological Profiles by Affinity Fingerprinting.
    Peragovics A; Simon Z; Malnasi-Csizmadia A; Bender A
    Curr Pharm Des; 2016; 22(46):6885-6894. PubMed ID: 27587199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MTLD, a Database of Multiple Target Ligands, the Updated Version.
    Chen C; Wu M; Cen S; Wu J; Zhou J
    Molecules; 2017 Sep; 22(9):. PubMed ID: 28878188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploration of the mechanism of traditional Chinese medicine by AI approach using unsupervised machine learning for cellular functional similarity of compounds in heterogeneous networks, XiaoErFuPi granules as an example.
    Guo F; Tang X; Zhang W; Wei J; Tang S; Wu H; Yang H
    Pharmacol Res; 2020 Oct; 160():105077. PubMed ID: 32687952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polypharmacology: The science of multi-targeting molecules.
    Kabir A; Muth A
    Pharmacol Res; 2022 Feb; 176():106055. PubMed ID: 34990865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative and systems pharmacology 2. In silico polypharmacology of G protein-coupled receptor ligands via network-based approaches.
    Wu Z; Lu W; Yu W; Wang T; Li W; Liu G; Zhang H; Pang X; Huang J; Liu M; Cheng F; Tang Y
    Pharmacol Res; 2018 Mar; 129():400-413. PubMed ID: 29133212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.
    Sumi NJ; Ctortecka C; Hu Q; Bryant AT; Fang B; Remsing Rix LL; Ayaz M; Kinose F; Welsh EA; Eschrich SA; Lawrence HR; Koomen JM; Haura EB; Rix U
    Cell Chem Biol; 2019 Sep; 26(9):1240-1252.e11. PubMed ID: 31257184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology.
    Albertini C; Salerno A; de Sena Murteira Pinheiro P; Bolognesi ML
    Med Res Rev; 2021 Sep; 41(5):2606-2633. PubMed ID: 32557696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds.
    Proschak E; Stark H; Merk D
    J Med Chem; 2019 Jan; 62(2):420-444. PubMed ID: 30035545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polypharmacology in Precision Oncology: Current Applications and Future Prospects.
    Antolin AA; Workman P; Mestres J; Al-Lazikani B
    Curr Pharm Des; 2016; 22(46):6935-6945. PubMed ID: 27669965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hybrid molecules: The privileged scaffolds for various pharmaceuticals.
    Shaveta ; Mishra S; Singh P
    Eur J Med Chem; 2016 Nov; 124():500-536. PubMed ID: 27598238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank.
    Pinzi L; Rastelli G
    J Chem Inf Model; 2020 Jan; 60(1):372-390. PubMed ID: 31800237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-target-based polypharmacology prediction (mTPP): An approach using virtual screening and machine learning for multi-target drug discovery.
    Liu K; Chen X; Ren Y; Liu C; Lv T; Liu Y; Zhang Y
    Chem Biol Interact; 2022 Dec; 368():110239. PubMed ID: 36309139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying Promiscuous Compounds with Activity against Different Target Classes.
    Feldmann C; Miljković F; Yonchev D; Bajorath J
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31752252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 7-Aminoalkoxy-Quinazolines from Epigenetic Focused Libraries Are Potent and Selective Inhibitors of DNA Methyltransferase 1.
    Medina-Franco JL; López-López E; Martínez-Fernández LP
    Molecules; 2022 Apr; 27(9):. PubMed ID: 35566242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.